Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Curr HIV/AIDS Rep ; 21(3): 87-115, 2024 06.
Article in English | MEDLINE | ID: mdl-38602558

ABSTRACT

PURPOSE OF REVIEW: Cannabis may have beneficial anti-inflammatory effects in people with HIV (PWH); however, given this population's high burden of persisting neurocognitive impairment (NCI), clinicians are concerned they may be particularly vulnerable to the deleterious effects of cannabis on cognition. Here, we present a systematic scoping review of clinical and preclinical studies evaluating the effects of cannabinoid exposure on cognition in HIV. RECENT FINDINGS: Results revealed little evidence to support a harmful impact of cannabis use on cognition in HIV, with few eligible preclinical data existing. Furthermore, the beneficial/harmful effects of cannabis use observed on cognition were function-dependent and confounded by several factors (e.g., age, frequency of use). Results are discussed alongside potential mechanisms of cannabis effects on cognition in HIV (e.g., anti-inflammatory), and considerations are outlined for screening PWH that may benefit from cannabis interventions. We further highlight the value of accelerating research discoveries in this area by utilizing translatable cross-species tasks to facilitate comparisons across human and animal work.


Subject(s)
Cognition , HIV Infections , Humans , HIV Infections/drug therapy , HIV Infections/complications , HIV Infections/psychology , Cognition/drug effects , Cannabis/adverse effects , Cannabinoids/therapeutic use , Cannabinoids/adverse effects , Cannabinoids/pharmacology , Animals , Cognitive Dysfunction/etiology , Cognitive Dysfunction/drug therapy , Marijuana Use/adverse effects
2.
Neuropharmacology ; 248: 109851, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38325772

ABSTRACT

Heightened risk-based decision-making is observed across several neuropsychiatric disorders including schizophrenia, bipolar disorder, and Parkinson's disease, yet no treatments exist that effectively normalize this aberrant behavior. Preclinical risk-based decision-making paradigms have identified the important modulatory roles of dopamine and sex in the performance of such tasks, though specific task parameters may alter such effects (e.g., punishment and reward values). Previous work has highlighted the role of dopamine 2-like receptors (D2R) during performance of the Risk Preference Task (RPT) in male rats, however sex was not considered as a factor in this study, nor were treatments identified that reduced risk preference. Here, we utilized the RPT to determine sex-dependent differences in baseline performance and impact of the D2R receptor agonist pramipexole (PPX), and antagonist sulpiride (SUL) on behavioral performance. Female rats exhibited heightened risk-preference during baseline testing. Consistent with human studies, PPX increased risk-preference across sex, though the effects of PPX were more pronounced in female animals. Importantly, SUL reduced risk-preference in these rats across sexes. Thus, under the task specifications of the RPT that does not include punishment, female rats were more risk-preferring and required higher PPX doses to promote risky choices compared to males. Furthermore, blockade of D2R receptors may reduce risk-preference of rats, though further studies are required.


Subject(s)
Dopamine , Sex Characteristics , Humans , Rats , Female , Male , Animals , Dopamine/pharmacology , Dopamine Agonists/pharmacology , Pramipexole/pharmacology , Receptors, Dopamine , Decision Making , Reward
3.
Front Pharmacol ; 12: 706703, 2021.
Article in English | MEDLINE | ID: mdl-34603019

ABSTRACT

Rationale: The endocannabinoidome mediators, N-Oleoylglycine (OlGly) and N-Oleoylalanine (OlAla), have been shown to reduce acute naloxone-precipitated morphine withdrawal affective and somatic responses. Objectives: To determine the role and mechanism of action of OlGly and OlAla in withdrawal responses from chronic exposure to opiates in male Sprague-Dawley rats. Methods: Opiate withdrawal was produced: 1) spontaneously 24 h following chronic exposure to escalating doses of morphine over 14 days (Experiments 1 and 2) and steady-state exposure to heroin by minipumps for 12 days (Experiment 3), 2) by naloxone injection during steady-state heroin exposure (Experiment 4), 3) by naloxone injection during operant heroin self-administration (Experiment 5). Results: In Experiment 1, spontaneous morphine withdrawal produced somatic withdrawal reactions. The behavioral withdrawal reactions were accompanied by suppressed endogenous levels of OlGly in the nucleus accumbens, amygdala, and prefrontal cortex, N-Arachidonylglycerol and OlAla in the amygdala, 2-arachidonoylglycerol in the nucleus accumbens, amygdala and interoceptive insular cortex, and by changes in colonic microbiota composition. In Experiment 2, treatment with OlAla, but not OlGly, reduced spontaneous morphine withdrawal responses. In Experiment 3, OlAla attenuated spontaneous steady-state heroin withdrawal responses at both 5 and 20 mg/kg; OlGly only reduced withdrawal responses at the higher dose of 20 mg/kg. Experiment 4 demonstrated that naloxone-precipitated heroin withdrawal from steady-state exposure to heroin (7 mg/kg/day for 12 days) is accompanied by tissue-specific changes in brain or gut endocannabinoidome mediator, including OlGly and OlAla, levels and colonic microbiota composition, and that OlAla (5 mg/kg) attenuated behavioural withdrawal reactions, while also reversing some of the changes in brain and gut endocannabinoidome and gut microbiota induced by naloxone. Experiment 5 demonstrated that although OlAla (5 mg/kg) did not interfere with operant heroin self-administration on its own, it blocked naloxone-precipitated elevation of heroin self-administration behavior. Conclusion: These results suggest that OlAla and OlGly are two endogenous mediators whose brain concentrations respond to chronic opiate treatment and withdrawal concomitantly with changes in colon microbiota composition, and that OlAla may be more effective than OlGly in suppressing chronic opiate withdrawal responses.

4.
Psychopharmacology (Berl) ; 237(9): 2753-2765, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32556401

ABSTRACT

RATIONALE: Oleoyl glycine, a little studied fatty acid amide similar in structure to anandamide, interferes with nicotine addiction in mice and acute naloxone-precipitated morphine withdrawal (MWD) in rats. Because endogenous oleoyl glycine is subject to rapid enzymatic deactivation, we evaluated the potential of more stable analogs to interfere with opiate withdrawal. OBJECTIVES: The potential of monomethylated oleoyl glycine (oleoyl alanine, HU595) to interfere with somatic and aversive effects of acute naloxone-precipitated MWD, its duration, and mechanism of action was assessed in male Sprague Dawley rats. The potential of dimethylated oleoyl glycine (HU596) to interfere with the aversive effects of naloxone-precipitated MWD was also investigated. RESULTS: Oleoyl alanine (HU595) interfered with somatic and aversive effects produced by naloxone-precipitated MWD at equivalent doses (1 and 5 mg/kg, i.p.) as we have reported for oleoyl glycine; however, oleoyl alanine produced a longer lasting (60 min) interference, yet did not produce rewarding or aversive effects on its own and did not modify locomotor activity. HU596 was not effective. The interference with aversive effects of naloxone-precipitated MWD by oleoyl alanine was prevented by both a PPARα antagonist and a CB1 receptor antagonist. Accordingly, the compound was found to inhibit FAAH and activate PPARα in vitro. Finally, oleoyl alanine also reduced acute naloxone-precipitated MWD anhedonia, as measured by decreased saccharin preference. CONCLUSIONS: Oleoyl alanine (also an endogenous fatty acid) may be a more stable and effective treatment for opiate withdrawal than oleoyl glycine.


Subject(s)
Alanine/therapeutic use , Analgesics, Opioid/adverse effects , Glycine/analogs & derivatives , Morphine/adverse effects , Naloxone/adverse effects , Oleic Acids/therapeutic use , Substance Withdrawal Syndrome/drug therapy , Alanine/analogs & derivatives , Animals , Glycine/chemistry , Glycine/therapeutic use , Male , Morphine Dependence/drug therapy , Morphine Dependence/psychology , Narcotic Antagonists/adverse effects , Oleic Acids/chemistry , Rats , Rats, Sprague-Dawley , Reward , Substance Withdrawal Syndrome/psychology
5.
Alcohol ; 87: 79-88, 2020 09.
Article in English | MEDLINE | ID: mdl-32497557

ABSTRACT

OBJECTIVE: The addition of sweeteners to alcoholic beverages is thought to facilitate heavy alcohol consumption, and this may be of particular concern when the additive is high fructose corn syrup (HFCS). METHODS: Four experiments in male Sprague-Dawley rats were performed to investigate whether the addition of 25% HFCS to ethanol (5%, 10%, and 20% v/v ethanol) would alter its intraoral operant self-administration, palatability, and sensitivity to food deprivation stress. RESULTS: As anticipated, HFCS drastically increased ethanol intake, and this effect appeared driven by its caloric value. Importantly, HFCS increased the persistence of operant responding following extinction in animals trained to self-administer the combination, and the addition of HFCS to ethanol changed subsequent responses to ethanol, including increased palatability and intake. CONCLUSIONS: These results in rats suggest that the addition of HFCS to the list of ingredients in sweetened alcoholic beverages could play a significant role in the harmful consumption of ethanol-containing beverages.


Subject(s)
Alcohol Drinking , Ethanol/administration & dosage , High Fructose Corn Syrup , Animals , Beverages , High Fructose Corn Syrup/administration & dosage , Male , Rats , Rats, Sprague-Dawley
6.
Psychopharmacology (Berl) ; 237(2): 375-384, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31712968

ABSTRACT

RATIONALE: Acute naloxone-precipitated morphine withdrawal (MWD) produces a conditioned place aversion (CPA) in rats even after one or two exposures to high-dose (20 mg/kg, sc) morphine followed 24-h later by naloxone (1 mg/kg, sc). However, the somatic withdrawal reactions produced by acute naloxone-precipitated MWD in rats have not been investigated. A recently discovered fatty acid amide, N-oleoylglycine (OlGly), which has been suggested to act as a fatty acid amide hydrolase (FAAH) inhibitor and as a peroxisome proliferator-activated receptor alpha (PPARα) agonist, was previously shown to interfere with a naloxone-precipitated MWD-induced CPA in rats. OBJECTIVES: The aims of these studies were to examine the somatic withdrawal responses produced by acute naloxone-precipitated MWD and determine whether OlGly can also interfere with these responses. RESULTS: Here, we report that following two exposures to morphine (20 mg/kg, sc) each followed by naloxone (1 mg/kg, sc) 24 h later, rats display nausea-like somatic reactions of lying flattened on belly, abdominal contractions and diarrhea, and display increased mouthing movements and loss of body weight. OlGly (5 mg/kg, ip) interfered with naloxone-precipitated MWD-induced abdominal contractions, lying on belly, diarrhea and mouthing movements in male Sprague-Dawley rats, by both a cannabinoid 1 (CB1) and a PPARα mechanism of action. Since these withdrawal reactions are symptomatic of nausea, we evaluated the potential of OlGly to interfere with lithium chloride (LiCl)-induced and MWD-induced conditioned gaping in rats, a selective measure of nausea; the suppression of MWD-induced gaping reactions by OlGly was both CB1 and PPARα mediated. CONCLUSION: These results suggest that the aversive effects of acute naloxone-precipitated MWD reflect nausea, which is suppressed by OlGly.


Subject(s)
Glycine/analogs & derivatives , Morphine/adverse effects , Naloxone/toxicity , Narcotic Antagonists/toxicity , Nausea/drug therapy , Oleic Acids/therapeutic use , Substance Withdrawal Syndrome/drug therapy , Animals , Female , Glycine/pharmacology , Glycine/therapeutic use , Male , Medically Unexplained Symptoms , Morphine Dependence/drug therapy , Morphine Dependence/physiopathology , Nausea/chemically induced , Nausea/physiopathology , Oleic Acids/pharmacology , Rats , Rats, Sprague-Dawley , Shrews , Substance Withdrawal Syndrome/etiology , Substance Withdrawal Syndrome/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...